# A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Study · id `cardio:ct-nct05536804` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05536804](<https://clinicaltrials.gov/study/NCT05536804>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05536804

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 134 participants.

## Technical summary

Registry record NCT05536804. Randomized; double masking; primary purpose treatment. Start 2023-02-08 (actual); primary completion 2026-07-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 134 participants (enrolled count; ClinicalTrials.gov record NCT05536804, source copy `cardio:ctgov-nct05536804-2026-09-11`, retrieved 2026-10-26)
- Started: 2023-02-08 (actual) (ClinicalTrials.gov record NCT05536804, source copy `cardio:ctgov-nct05536804-2026-09-11`, retrieved 2026-10-26)
- Primary completion: 2026-07-06 (actual) (ClinicalTrials.gov record NCT05536804, source copy `cardio:ctgov-nct05536804-2026-09-11`, retrieved 2026-10-26)
- Completion: 2026-07-30 (actual) (ClinicalTrials.gov record NCT05536804, source copy `cardio:ctgov-nct05536804-2026-09-11`, retrieved 2026-10-26)
- Countries: United States; Austria; Canada; Denmark; Mexico; Netherlands (ClinicalTrials.gov record NCT05536804, source copy `cardio:ctgov-nct05536804-2026-09-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05536804-2026-09-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
- Acronym: TREASURE-CKD
- Condition: Overweight
- Condition: Obesity
- Condition: Chronic Kidney Disease
- Condition: Type 2 Diabetes
- Condition: T2D
- Intervention (Drug): Tirzepatide
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Tirzepatide (`cardio:tirzepatide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 034880d0ed1c50f8505529b69853aeae5e52239aa108901e1265430b9bf14e2e
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
